Key result
Bosentan 200 mg IV decreased systolic blood pressure (P<0.05) and increased coronary diameter (P<0.01) in patients with stable coronary artery disease.
Why the study?
Does the endothelin antagonist bosentan improve systemic and coronary hemodynamics in patients with stable coronary artery disease?
Population
28 patients with angiographically documented stable coronary artery disease
Comparison
Bosentan 200 mg IV vs Placebo
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
acute (immediate post-IV administration)
Authors
Loading...
Bosentan improves coronary hemodynamics in CAD; confirms endothelin’s role in tone and leaves open therapeutic potential.
RCT (n=28)
Double-blind
randomized
Does the endothelin antagonist bosentan improve systemic and coronary hemodynamics in patients with stable coronary artery disease?
Acute administration of the endothelin antagonist bosentan induces epicardial coronary vasodilation in patients with stable CAD, demonstrating that endogenous endothelin exerts a baseline vasoconstrictor tone.
Wenzel et al. (1998) conducted an RCT in stable coronary artery disease (n=28). Bosentan vs. Placebo was evaluated on systemic and coronary hemodynamics. Bosentan 200 mg IV decreased systolic blood pressure (P<0.05) and increased coronary diameter (P<0.01) in patients with stable coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: